Dropout Rate for Taking Sovaldi: 400% Higher Than Observed in Clinical Trials
Share
Follow Us
The Editors at Hepatitis Central
October 7, 2014
Learn about the financial impact for Hep C patients who are failing to complete their full, 12-week course of drug therapy with Sovaldi.
CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill
By David Kroll, 9/17/14
Over 8 percent of hepatitis C patients taking Sovaldi (sofosbuvir; Gilead) are failing to complete their full, 12-week course of drug therapy, a dropout rate roughly four times that observed in clinical trials.
By discontinuing the drug, shown to have a 90+% cure rate, these patients (and their insurance providers) are incurring health care costs of $28,000 or $56,000, without knowing if they are rid of the virus.
Continue reading this entire article:
http://www.forbes.com/sites/davidkroll/2014/09/17/one-in-12-hepatitis-c-patients-not-adhering-to-1000day-pill/
